Trending Now
Party City Holdco Inc (NYSE:PRTY) is surging and here’s why
Party City Holdco Inc (NYSE:PRTY) is surging and here are few reasons
1. The shares are oversold after a...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Seres Therapeutics Inc. (NASDAQ:MCRB) Reported Positive Topline Results from the Pivotal...
Seres Therapeutics Inc. (NASDAQ:MCRB) is thrilled with the results from an oral microbiome therapeutic; SER-109, treatment for recurrent C. difficile infection (CDI). Results from...
MAKE IT MODERN
LATEST REVIEWS
Heat Biologics Inc (NASDAQ: HTBX) Announces Robust T Cell-Mediated Immune Response...
The outbreak of the novel beta-coronavirus from Wuhan, China, has left to over half of the world's population in a status of panic and...
MAKE IT MODERN
PERFORMANCE TRAINING
Invesco QQQ Trust Series 1 (QQQ) hits all time high and may not stop
The QQQ’s made new 12 month highs again this morning, continuing to grind higher ahead of the FED meeting next week.
Longeveron Inc. (NASDAQ: LGVN) Announces Orphan Drug Designation Grant For Lomecel-B Drug on HLHS
Longeveron Inc. (NASDAQ: LGVN) has announced that the FDA has granted its Lomecel-B drug for Hypoplastic Left Heart Syndrome treatment an Orphan Drug Designation....
Halozyme’s ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment
Subcutaneous Convenience, Uncompromised Efficacy
Halozyme Therapeutics (NASDAQ: HALO), a leader in innovative drug delivery solutions, recently announced a significant...
TRACON Pharmaceuticals (NASDAQ:TCON) Reports Study Results Of Envafolimab In MSI-HdMMR Colorectal Cancer
TRACON Pharmaceuticals (NASDAQ:TCON) has released updated clinical results from its pivotal envafolimab study in MSI-H/dMMR cancer patients. TRACON’s corporate partners Alphamab Oncology and 3D...
United Therapeutics Corporation (NASDAQ: UTHR) Receives Response From The FDA Regarding Tyvaso NDA
United Therapeutics Corporation (NASDAQ: UTHR) has offered an update on the US FDA review for its New Drug Application (NDA) for Tyvaso DPI for...
MAKE IT MODERN
